» 
NIDA funds studies
Copy URL
https://www.pharmnovo.com/post/nida-funds-studies

NIDA funds studies

January 30, 2024

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

The persistent challenge of opioid addiction, involving substances such as heroin, fentanyl, and oxycodone, remains a significant public health concern both in the United States and globally. A key obstacle in addressing this addiction crisis is the management of withdrawal symptoms. The symptoms include intensified pain, nausea, excessive sweating, and mental health issues like depression and anxiety. Often resembling a severe flu, these symptoms can be life-threatening, and the fear of experiencing these symptoms contributes to opioid users’ reluctance to stop taking their drug.

The interest of NIDA in PN6047, prompted by the drug's very positive effects on neuropathic pain, reflects the ongoing efforts of NIDA to find effective treatments for opioid withdrawal.

Comprehensive data from preclinical studies suggest that PN6047 has no abuse potential. This is further supported by Phase I clinical data, where no side effects indicating abuse potential have been observed. Ongoing studies in the NIDA project have also demonstrated the candidate’s effectiveness in pain relief during intensified pain due to opioid withdrawal and its potential to alleviate symptoms of depression and anxiety.

Phase I study data of PN6047 have shown promising results regarding safety and tolerability, paving the way for additional studies of PN6047 in opioid withdrawal syndrome, with a potential for support from NIDA.

Author:
Copy URL
https://www.pharmnovo.com/post/nida-funds-studies

NIDA funds studies

January 30, 2024

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

The persistent challenge of opioid addiction, involving substances such as heroin, fentanyl, and oxycodone, remains a significant public health concern both in the United States and globally. A key obstacle in addressing this addiction crisis is the management of withdrawal symptoms. The symptoms include intensified pain, nausea, excessive sweating, and mental health issues like depression and anxiety. Often resembling a severe flu, these symptoms can be life-threatening, and the fear of experiencing these symptoms contributes to opioid users’ reluctance to stop taking their drug.

The interest of NIDA in PN6047, prompted by the drug's very positive effects on neuropathic pain, reflects the ongoing efforts of NIDA to find effective treatments for opioid withdrawal.

Comprehensive data from preclinical studies suggest that PN6047 has no abuse potential. This is further supported by Phase I clinical data, where no side effects indicating abuse potential have been observed. Ongoing studies in the NIDA project have also demonstrated the candidate’s effectiveness in pain relief during intensified pain due to opioid withdrawal and its potential to alleviate symptoms of depression and anxiety.

Phase I study data of PN6047 have shown promising results regarding safety and tolerability, paving the way for additional studies of PN6047 in opioid withdrawal syndrome, with a potential for support from NIDA.

Author:

Latest news

View all
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Visionaries in pain relief: PharmNovo presents Bengt von Mentzer, founder and Chief scientific advisor.

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.

Read more
January 30, 2024

A new perspective in pain management and opioid withdrawal relief

We are proud to share an article in Dagens Industri about our groundbreaking work with PN6047. Our promising drug candidate not only has the potential to revolutionise pain relief but has also caught the attention of the National Institute on Drug Abuse (NIDA) for its role in opioid withdrawal treatment. Per von Mentzer, our CEO, states: "Our work with PN6047 could open new paths in pain relief. Particularly in neuropathic pain, our research could lead to new insights and novel treatment approaches in various clinical areas." PN6047, a selective DORA, offers a new perspective on both pain management and opioid withdrawal treatment. The results from the Phase I study show promising safety and tolerance, paving the way for further studies on its effects on opioid withdrawal syndrome.

Read more